{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Tackling Existential Crisis","description":"Summary In this episode of the Med City Pivot Podcast, host Arundhati Parmar speaks with Lars Petersen about one of the most remarkable corporate transformations in modern business history. Facing a catastrophic collapse of its core film business in the mid-2000s due to the rise of digital photography, Fujifilm executed a bold and strategic pivot into healthcare and life sciences. The company diversified aggressively, leveraging its deep expertise in materials science, imaging, and innovation to build a thriving biotechnology and medical technology ecosystem. Today, Fujifilm operates as a global Contract Development and Manufacturing Organization (CDMO), partnering with leading pharmaceutical companies and startups alike. The conversation explores how strategic investment, diversification, long-term thinking, and innovation\u2014including AI\u2014enabled Fujifilm not just to survive, but to lead in a completely new industry. Links &amp;amp; Resources   Connect with Arundhati Parmar   aparmar@medcitynews.com&amp;nbsp;   https:\/\/twitter.com\/aparmarbb?lang=en   https:\/\/medcitynews.com\/   Keywords Fujifilm Pivot Healthcare CDMO Biotechnology Biologics digital transformation business strategy Innovation AI in healthcare Pharma Manufacturing monoclonal antibodies gene therapy cell therapy Diversification corporate strategy MedTech Episode Highlights&amp;nbsp;   00:00\u201300:23 \u2013 Introduction to the concept of \u201cpivot\u201d and Fujifilm\u2019s survival story   00:00\u201300:47 \u2013 The collapse of the film industry and existential crisis   00:00\u201301:15 \u2013 Fujifilm\u2019s transformation into a healthcare company   00:02:39\u201300:03:28 \u2013 2006: the pivotal year and 60% revenue loss   00:03:28\u201300:03:45 \u2013 Strategic decision to diversify long-term   00:04:22\u201300:05:08 \u2013 Why Fujifilm succeeded while competitors failed   00:05:35\u201300:06:26 \u2013 Key investments and acquisitions (including Biogen assets)   00:06:52\u201300:07:30 \u2013 Why healthcare is a stable, long-term growth industry   00:07:53\u201300:08:29 \u2013 Expansion into medical devices and imaging technologies   00:09:42\u201300:10:34 \u2013 Core therapeutic focus: biologics, gene therapy, cell therapy   00:10:49\u201300:11:22 \u2013 Serving both startups and global pharma giants   00:12:39\u201300:13:40 \u2013 Competitive positioning vs. Samsung Biologics &amp;amp; Lonza   00:15:08\u201300:15:44 \u2013 \u201cPartners for life\u201d philosophy and long-term trust   00:17:52\u201300:18:49 \u2013 AI integration across manufacturing ecosystems   00:18:54\u201300:19:42 \u2013 Final takeaway: building shared ecosystems for the future of medicine   ","author_name":"MedCity Pivot","author_url":"http:\/\/medcitypivot.libsyn.com\/website","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/40651720\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/200215155"}